The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index; 7 of the 25 sources its claims cite were checked for support.
Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services
Open accessAbstract
OBJECTIVES: Glucagon-like peptide 1 receptor agonists (GLP1-RA) are indicated for the treatment of type 2 diabetes and more recently for weight loss. The aim of this study was to assess the risks associated with GLP1-RA exposure during early pregnancy. DESIGN: This multicentre, observational prospective cohort study compared pregnancy outcomes in women exposed to GLP1-RA in early pregnancy either for diabetes or obesity treatment with those in two reference groups: (1) women with diabetes exposed to at least one non-GLP1-RA antidiabetic drug during the first trimester and (2) a reference group of overweight/obese women without diabetes, between 2009 and 2022. SETTING: Data were collected from the databases of six Teratology Information Services. PARTICIPANTS: This study included 168 pregnancies of women exposed to GLP1-RA during the first trimester, alongside a reference group of 156 pregnancies of women with diabetes and 163 pregnancies of overweight/obese women. RESULTS: Exposure to GLP1-RA in the first trimester was not associated with a risk of major birth defects when compared with diabetes (2.6% vs 2.3%; adjusted OR, 0.98 (95% CI, 0.16 to 5.82)) or to overweight/obese (2.6% vs 3.9%; adjusted OR 0.54 (0.11 to 2.75)). For the GLP1-RA group, cumulative incidence for live births, pregnancy losses and pregnancy terminations was 59%, 23% and 18%, respectively. In the diabetes reference group, corresponding estimates were 69%, 26% and 6%, while in the overweight/obese reference group, they were 63%, 29% and 8%, respectively. Cox proportional cause-specific hazard models indicated no increased risk of pregnancy losses in the GLP1-RA versus the diabetes and the overweight/obese reference groups, in both crude and adjusted analyses. CONCLUSIONS: This study offers reassurance in cases of inadvertent exposure to GLP1-RA during the first trimester of pregnancy. Due to the limited sample size, larger studies are required to validate these findings.
Overview
CoChat Summary
TL;DR
In this multicentre prospective cohort of 168 first-trimester GLP1 receptor agonist (GLP1-RA) exposures, the study found no increased risk of major birth defects or pregnancy loss versus two reference groups. The authors conclude the findings are reassuring for inadvertent early-pregnancy exposure, but the sample was too small for definitive conclusions.
Key findings
- Among 168 GLP1-RA-exposed pregnancies, major birth defects occurred in 2.6%; compared with 2.3% in women with diabetes, the adjusted OR was 0.98 (95% CI, 0.16 to 5.82), and compared with overweight/obese women it was 0.54 (95% CI, 0.11 to 2.75).
- Cumulative incidence in the GLP1-RA group was 59% live births, 23% pregnancy losses, and 18% pregnancy terminations; the corresponding estimates were 69%/26%/6% in the diabetes reference group and 63%/29%/8% in the overweight/obese reference group.
- Cause-specific Cox models found no increased risk of pregnancy loss versus either reference group; however, termination of pregnancy was higher versus the diabetes group (adjusted HR 3.89; 95% CI, 1.48 to 10.2) but not versus the overweight/obese group (adjusted HR 1.39; 95% CI, 0.66 to 2.93).
- In the exposed group, liraglutide was most common (n=99), followed by semaglutide (n=51), dulaglutide (n=11), and exenatide (n=7); 70% used GLP1-RA for weight loss.
Methods
- Multicentre, observational, prospective cohort study using data from six Teratology Information Services in five countries (Germany, Israel, Italy, Switzerland, UK), covering pregnancies from 2009 to 2022.
- Included 168 pregnancies with first-trimester GLP1-RA exposure and two reference groups: 156 pregnancies in women with diabetes exposed to non-GLP1-RA antidiabetic drugs, and 163 pregnancies in overweight/obese women without diabetes.
- Main analyses used multivariable logistic regression for major birth defects and cause-specific Cox proportional hazard models with cumulative incidence functions for pregnancy loss and termination, adjusting for maternal age, prior pregnancies, polymedication, and other listed covariates.
Limitations
- The paper states the sample size was limited and “not large enough to draw firm and definitive conclusions.”
- The authors state that HbA1c and other severity markers were not systematically available, limiting assessment of diabetes severity.
- The text makes evident that GLP1-RA were analyzed as a single homogeneous group, so drug-specific risks for individual agents could not be well assessed; it also notes that exposure often stopped early in gestation, so full first-trimester exposure was not always present.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
6 Valid · 0 Not valid · 9 Not checked · 52 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In a multinational population-based cohort study involving 51,826 pregnant women diagnosed with type 2 diabetes and their infants, the standardised prevalence of major congenital malformations was 8.3% among infants with periconceptional exposure to GLP1-RA (n=938).12”
§ Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services > Introduction
What the sources say
- Supportedcites [12] Cesta, 2024, Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy, JAMA Intern Med source
The Results (Prevalence of Malformations; page unavailable) report a standardized weighted prevalence of 8.23% for major congenital malformations among infants with periconceptional GLP-1 receptor agonist exposure, very close to the cited 8.3%. The Results (Study Population and Exposure Groups; page unavailable) identify 51,826 pregnancies in women with type 2 diabetes and 938 with GLP-1 receptor agonist exposure. (LLM, conf=0.85)
plainn = 938- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Compared with insulin, there was no increased risk of major congenital malformations (adjusted relative risk 0.95, 95% CI, 0.72 to 1.26) for infants exposed to GLP1-RA.”
§ Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services > Introduction
What the sources say
- Supportedcites [12] Cesta, 2024, Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy, JAMA Intern Med source
Table 2 (Results, Relative Risks of Malformations) reports an adjusted relative risk of 0.95 (95% CI, 0.72–1.26) for any major congenital malformation after periconceptional GLP-1 receptor agonist exposure, with insulin as the reference. The Conclusions likewise state that the study did not observe a greater risk compared with insulin. (LLM, conf=0.95)
plainn = 938- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Information on follow-up was obtained from healthcare professionals and patients in similar proportions for both the GLP1-RA and the reference groups with diabetes and who were overweight/obese: healthcare professionals 10% vs 9% and 6% and patients 90% vs 91% and 94%, respectively.”
§ Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services > Results > Follow-up
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of infants classified as LGA were higher in the GLP1-RA exposed group and in the diabetes reference group compared with the overweight/obese reference group.”
§ Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services > Results > Pregnancy outcomes
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 483 women were included in the cumulative incidence analysis, including 167 in the GLP1-RA group, 154 in the diabetes reference group and 162 in the overweight/obese reference group.”
§ Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services > Results > Pregnancy outcomes
plainn = 483- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
16 more claims
Create a free account to see all 67 claims and to verify the 2 references still open.
- Probably not a substantial claim. 37
- It may state two separate claims as one. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In one relatively small study (n = 168), GLP-1RA use was not associated with an increased risk of pregnancy loss or birth defects in humans (110).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [110]
Citations
Cites
Unintended pregnancy: worldwide levels, trends, and outcomes.
Singh, S., Sedgh, G., & Hussain, R. (2010) · Studies in Family Planning · doi:10.1111/j.1728-4465.2010.00250.x · Cited by 731
Update on overall prevalence of major birth defects - Atlanta, Georgia, 1978-2005: (403792008-002)
(2008) · PsycEXTRA Dataset · doi:10.1037/e403792008-002 · Cited by 409 · cited 1×
“12 29 This rate is also equivalent to that observed in the reference group with diabetes in our study (2.3%).”
ResultInfluentialBell, R., Glinianaia, S. V., Tennant, P. W. G., Bilous, R. W., & Rankin, J. (2012) · Diabetologia · doi:10.1007/s00125-012-2455-y · Cited by 224 · cited 1×
“34 Unfortunately, we lacked systematic access to glycated haemoglobin values, which could have indicated that cases in our study population were with well-managed diabetes inadvertently selected leading to a rate of birth defects similar to the general population.”
BackgroundSafety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy
Cesta, C. E., Rotem, R., Bateman, B. T., Chodick, G., Cohen, J. M., Furu, K., Gissler, M., Huybrechts, K. F., Kjerpeseth, L. J., Leinonen, M. K., et al. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.6663 · Cited by 200
Muller, D. R. P., Stenvers, D. J., Malekzadeh, A., Holleman, F., Painter, R. C., & Siegelaar, S. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1215356 · Cited by 174
Tinker, S. C., Gilboa, S. M., Moore, C. A., Waller, D. K., Simeone, R. M., Kim, S. Y., Jamieson, D. J., Botto, L. D., & Reefhuis, J. (2019) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2019.08.028 · Cited by 161
The Placental Barrier: the Gate and the Fate in Drug Distribution
Tetro, N., Moushaev, S., Rubinchik-Stern, M., & Eyal, S. (2018) · Pharmaceutical Research · doi:10.1007/s11095-017-2286-0 · Cited by 145 · cited 1×
“18 While previous studies did not detect an increased risk of major birth defects following the use of GLP1-RA during the first trimester of pregnancy, further confirmation from additional studies is warranted.”
ResultPregnancy outcome following maternal exposure to statins: a multicentre prospective study
Winterfeld, U., Allignol, A., Panchaud, A., Rothuizen, L. E., Merlob, P., Cuppers‐Maarschalkerweerd, B., Vial, T., Stephens, S., Clementi, M., Santis, M. D., et al. (2012) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.12066 · Cited by 126
Self-citationSchaefer, C., Ornoy, A., Clementi, M., Meister, R., & Weber‐Schoendorfer, C. (2008) · Reproductive Toxicology · doi:10.1016/j.reprotox.2008.05.064 · Cited by 99
Self-citationSingh, G. K., & DiBari, J. N. (2019) · Journal of Obesity · doi:10.1155/2019/2419263 · Cited by 90
Research works printed but not linked: 2
- Lau, 2023, Semaglutid in der Adipositastherapie: Viel Diskussionsstoff, Dtsch Arztebl, 120, A
- Organization of Teratology Information Specialists (OTIS) . Mother to baby | fact sheets [Internet]. In: Critical periods of development. 2021. Available: https://www.ncbi.nlm.nih.gov/books/NBK582659/
Cited by
Glucagon-like peptide-1 receptor agonist use in pregnancy: a review
Drummond, R. F., Seif, K. E., & Reece, E. A. (2024) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2024.08.024 · Cited by 110
Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation
Maya, J., Pant, D. B., Fu, Y.-R., James, K., Batlle, C. I., Hsu, S., Soria-Contreras, D., Shook, L., Mow, C., Hivert, M., et al. (2025) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2025.20951 · Cited by 75
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 81
“…are not teratogenic and have not been associated with an imbalance in maternal outcomes or major birth defects, including fetal cardiac or kidney malformations, following inadvertent exposure in the first trimester in women with T2D ( n = 1,826) 76 or women with T2D or obesity ( n = 168) 77 .”
Imbroane, M. R., LeMoine, F., & Nau, C. (2025) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.01.019 · Cited by 69
Wyckoff, J., Lapolla, A., Asias-Dinh, B. D., Barbour, L. A., Brown, F. M., Catalano, P. M., Corcoy, R., Renzo, G. C. D., Drobycki, N., Kautzky‐Willer, A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf288 · Cited by 59
“Another observational cohort study (118) providing indirect evidence evaluated exposure of GLP-1RAs for obesity and T2DM in early pregnancy (27.4% of the study population) and reported no difference in congenital anomalies, spontaneous abortions, or increased numbers of LGA or SGA neonates compared…”
Influential
Metadata
- Authors
- Dao, K., Shechtman, S., Weber-Schoendorfer, C., Diav-Citrin, O., Murad, R. H., Berlin, M., Hazan, A., Richardson, J. L., Eleftheriou, G., Rousson, V., Diezi, L., Haefliger, D., Simões-Wüst, A. P., Addor, M.-C., Baud, D., Lamine, F., Panchaud, A., Buclin, T., Girardin, F. R., & Winterfeld, U.
- Affiliations
- Centre Hospitalier Universitaire Vaudois (CH)
- Israel Ministry of Health (IL)
- Charité - Universitätsmedizin Berlin, Pharmakovigilanzzentrum Embryonaltoxikologie, Institut für Klinische Pharmakologie und Toxikologie, Berlin, Germany
- The Israeli Teratology Information Service, Ministry of Health, Jerusalem, Israel
- Tel Aviv University (IL)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Ospedale Papa Giovanni XXIII (IT)
- University of Lausanne (CH)
- Swiss Teratogen Information Service and Clinical Pharmacology Service, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland
- Department of Obstetrics, University Hospital Zurich, University of Zurich, Zurich, Switzerland
- Endocrinology, Diabetes and Metabolism Service, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
- University of Bern (CH)
- Corresponding author
- Winterfeld, Ursula
- ORCID
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2024-04
- Volume
- 14
- Issue
- 4
- Pages
- e083550
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC11043712
- OpenAlex
- W4395468671
- Cited by
- 110
- References
- 24
- Citations by year
- 2026: 49 · 2025: 54 · 2024: 7
- FWCI
- 45.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- BMJ Open (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (submittedVersion, cc-by)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- IRIS (submittedVersion, cc-by)
- HighWire Press Open Archive (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Swiss National Science Foundation (SNSF 320030_214844)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Keywords
- GLP-1 receptor agonists, early pregnancy, teratogenicity, congenital malformations, miscarriage, live birth, reproductive safety, type 2 diabetes, obesity, antidiabetic drugs, anti-obesity drugs
- MeSH terms
- Abnormalities, Drug-Induced, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Obesity, Pregnancy, Pregnancy Complications, Pregnancy in Diabetics, Pregnancy Outcome, Pregnancy Trimester, First, Prospective Studies, Databases, Factual
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. https://app.cochat.ai/papers/10.1136/bmjopen-2023-083550
- The paper
- Dao, K., Shechtman, S., Weber-Schoendorfer, C., Diav-Citrin, O., Murad, R. H., Berlin, M., Hazan, A., Richardson, J. L., Eleftheriou, G., Rousson, V., Diezi, L., Haefliger, D., Simões-Wüst, A. P., Addor, M.-C., Baud, D., Lamine, F., Panchaud, A., Buclin, T., Girardin, F. R., & Winterfeld, U. (2024). Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open. https://doi.org/10.1136/bmjopen-2023-083550
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
